Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 10/20 | 0.41 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.37 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.37 |
| ▸ | TLR2 | O60603 | 1/20 | 0.36 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38661146 | 1.00 | TBXAS1 (0.41) | TBXAS1CYP24A1TBXA2RTLR2PLA2G4A | |
| SCHEMBL31204175 | 1.00 | TBXAS1 (0.41) | TBXAS1CYP24A1TBXA2RTLR2PLA2G4A | |
| SCHEMBL31204025 | 1.00 | TBXAS1 (0.41) | TBXAS1CYP24A1TBXA2RTLR2PLA2G4A | |
| SCHEMBL38660965 | 1.00 | TBXAS1 (0.41) | TBXAS1CYP24A1TBXA2RTLR2PLA2G4A | |
| SCHEMBL31204284 | 1.00 | TBXAS1 (0.41) | TBXAS1CYP24A1TBXA2RTLR2PLA2G4A | |
| SCHEMBL25299195 | 1.00 | TBXAS1 (0.41) | TBXAS1CYP24A1TBXA2RTLR2PLA2G4A | |
| SCHEMBL38662147 | 1.00 | TBXAS1 (0.41) | TBXAS1CYP24A1TBXA2RTLR2PLA2G4A | |
| SCHEMBL24587006 | 1.00 | TBXAS1 (0.41) | TBXAS1CYP24A1TBXA2RTLR2PLA2G4A | |
| SCHEMBL24587752 | 0.99 | TBXAS1 (0.38) | TBXAS1CYP24A1TBXA2RTLR2PLA2G4A | |
| SCHEMBL24587444 | 0.97 | TBXAS1 (0.39) | TBXAS1CYP24A1TBXA2RTLR2PLA2G4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026101900-A1 | NOVEL HYDROXY CYCLOALKYL CONTAINING LIPID COMPOUNDS AND METHODS OF THEIR USE | Acuitas Therapeutics, Inc. (CA) | 2026-05-15 | — | — | WO | disclosed |
| EP-4727913-A1 | LIPIDS FOR USE IN LIPID NANOPARTICLES | Acuitas Therapeutics, Inc. (CA) | 2026-04-22 | — | — | EP | disclosed |
| US-20240423915-A1 | LIPIDS FOR USE IN LIPID NANOPARTICLES | Acuitas Therapeutics, Inc. (CA) | 2024-12-26 | — | — | US | disclosed |
| WO-2024259322-A1 | LIPIDS FOR USE IN LIPID NANOPARTICLES | Acuitas Therapeutics, Inc. (CA) | 2024-12-19 | — | — | WO | disclosed |
| US-20230357133-A1 | NANOMATERIALS COMPRISING CARBONATES | BEAM THERAPEUTICS INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230357133-A1 | NANOMATERIALS COMPRISING CARBONATES | BEAM THERAPEUTICS INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230357133-A1 | NANOMATERIALS COMPRISING CARBONATES | BEAM THERAPEUTICS INC. | 2023-11-09 | — | — | US | disclosed |
| EP-4262818-A1 | NANOMATERIALS COMPRISING CARBONATES | Beam Therapeutics Inc. (US) | 2023-10-25 | — | — | EP | disclosed |
| CN-116685332-A | Nanomaterial comprising carbonate | 比姆医疗股份有限公司 | 2023-09-01 | — | — | CN | disclosed |
| WO-2022140239-A1 | NANOMATERIALS COMPRISING CARBONATES | BEAM THERAPEUTICS INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022140239-A1 | NANOMATERIALS COMPRISING CARBONATES | BEAM THERAPEUTICS INC. (US) | 2022-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357133-A1 | NANOMATERIALS COMPRISING CARBONATES | PHOSPHO1, CA13, SGMS2 | TBXAS1 2662/4885CYP24A1 384/4885TBXA2R 2774/4885 |
| US-20240423915-A1 | LIPIDS FOR USE IN LIPID NANOPARTICLES | PHOSPHO1, SGMS1, NPC1 | TBXAS1 636/4885CYP24A1 2027/4885TBXA2R 669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.